Latest News

​​StageZero Life Sciences Enters European Market with Oncore Pharma and BodyCheck NL; Multi-Year Agreement Valued at US$40 million

Toronto, Ontario, October 10, 2019 — StageZero Life Sciences, Ltd (TSX:SZLS) (“StageZero” or the “Company”), a life sciences company dedicated to the early detection of cancer and multiple disease states through whole blood, announced today that its licensing partner, Oncore Pharma, has signed a multi-year agreement with BodyCheck NL for the distribution and sale of ColonSentry® throughout the Netherlands, Belgium and Luxembourg (the “Benelux”).

LEARN MORE

Introducing StageZero Life Sciences

StageZero Life Sciences, Ltd. is dedicated to the early detection of cancer and multiple disease states through whole blood. Our next generation test, Aristotle®, is a multi-cancer panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle is built on our proprietary mRNA technology platform, which was validated on 10,000 patients and used to develop the first liquid biopsy for Colorectal Cancer. Further validation of the Aristotle test is currently underway.

Learn more

We Offer Blood Tests for the four Most Prevalent Cancers

Colorectal Cancer
​Lung Cancer
Prostate Cancer 
Breast Cancer

---

Something Small is Happening - And It's Pretty Big!                                

Small, Subtle Changes in Your Messenger RNA (mRNA) Can Identify Cancer Early - And We've Developed the Science that Finds Them

Most people think of cancer as changes, or mutations, in the sequence of DNA that lead to uncontrolled cell division. However, in between DNA and proteins (your cell's building blocks) is another layer of information called messenger RNA (mRNA) and it’s a crucial link to finding cancer. Changes in mRNA expression can be measured in blood and serve as specific early cancer indicators for cancer and other diseases. StageZero Life Sciences discovered this principle, named it the Sentinel Principle, and patented the technology platform behind it. The Sentinel Principle has already been used to develop the first liquid biopsy for Colorectal Cancer (ColonSentry®) and is the foundation of Aristotle® - our next generation test for multiple cancers.

Proven ... Not Promised.

Why ​We're Different

While most companies are working on building the science behind their blood tests for early cancer detection, our science has already been built, proven and validated.

Our Science

We Empower Physicians to Find Cancer Early

Our easy-to-read reports identify your patients' cancer risks and provide guidance​ for appropriate clinical interventions. We currently offer advanced biomarker testing for Colorectal, Lung, Prosate and Breast Cancers. Enroll your practice today, and be on the cutting edge of early cancer detection.

GET STARTED

We Give Patients a Head Start Against Cancer

The worst cancer diagnosis is a late one, yet more than 40% of cancers are still found in the later stages.  We offer advanced biomarker testing for prostate, lung and breast cancer, including our mRNA test for Colorectal Cancer. Talk to your doctor about getting tested.

Learn More

I Would Like Information About Your Tests

Fill out my online form

Latest News

References

1. Siegel RL, Miller KD, Jemal A. Cancer Statistics 2017. CA Cancer J Clin. 2017; 1: 7-30